Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.

Abstract

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

Keywords: COVID-19; baricitinib; hyper-inflammation.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Azetidines
  • COVID-19 Drug Treatment*
  • Humans
  • Purines
  • Pyrazoles
  • Retrospective Studies
  • SARS-CoV-2
  • Sulfonamides
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Azetidines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • baricitinib